About Us

Sustainable, Eco-friendly Biology for Crop Science, Food Safety, and Animal Health

OmniLytics, Incorporated is a biotech company that is focused on developing solutions for infectious disease and pest control. With decades of experience, OmniLytics produces and sells commercially tens of thousands of liters of product every year.

Located in Sandy, Utah, OmniLytics is pioneering research and development of bacteriophage solutions for pathogen control in the agricultural, food & water, industrial, pharmaceutical, and defense markets.

Our proprietary formulas and processes optimize the use of bacteriophage for commercial applications. OmniLytics is an R&D and manufacturing entity that derives its revenue from the sale of its products directly into specific markets or licensing agreements with its business units (subsidiaries) and strategic partners.

OmniLytics’ historical background dates back to 1954 and includes expansive research, development, knowledge, and expertise using bacteriophages to control dangerous pathogens in various market segments. As a result of this work, the company has developed many successful products to control destructive plant and animal bacterial diseases that have become resistant to traditional antimicrobial agents.

OmniLytics’ products consist of bacteriophage mixtures. Phages are very specific and only kill a particular species of bacteria. Unlike antibiotics and other chemicals, they will not kill other “good” bacteria, beneficial microflora, or fauna. As a result, the company’s products provide an alternative to synthetically produced chemicals that leave behind toxic residues that can adversely affect human health and the environment. OmniLytics’ EPA registered products have received exemptions for Maximum Residue Limits (MRLs) and have only a 4 hour re-entry interval (REI) for farm workers. Phages cannot infect human cells.

Bacterial viruses were discovered independently by Frederick Twort in 1915 and Felixd’ Herelle in 1917. At that time, not knowing what had caused the “clear spots” or “lyses” of bacterial colonies, d’ Herelle, a French–Canadian, designated the phenomenon “bacteriophage” which is translated “bacteria-eaters”. During the following two decades bacteriophage were proved to be viruses that attack only bacteria. d’ Herelle’s label and its diminutive version, phage, have become universally accepted by the scientific community and are synonymous with bacterial virus.

Over the past several decades, a major health and agricultural crises has developed due to the overuse and misuse of common antibiotics and chemicals. Multiple-drug resistance of bacterial pathogens is an increasing problem, especially in clinical environments. Many in the healthcare community believe this to be one of the greatest challenges in treating nosocomial (hospital) infections. This has become a most serious public health and economic threat for the new millennium.

OmniLytics believes phage therapy will be part of a fast-growing revolution in determining how patients and crops will be treated in the future.

Changing the way the world treats bacterial diseases.